

## THE USE OF DRIVING IMPAIRING MEDICINES, ALCOHOL AND OTHER PSYCHOACTIVE SUBSTANCES IN THE POPULATION OF PROFESSIONAL DRIVERS

**Roland Antonić<sup>1\*</sup>, Milica Pešić Ivanović<sup>2</sup>, Danijela Jevtić<sup>3</sup>,  
Slobodanka Bogdanović Vasić<sup>1</sup>, Kosana Popović<sup>1</sup>, Nikola Beljić<sup>1</sup>,  
Danijela Damnjanović<sup>1</sup>, Slobodan Janković<sup>4,5</sup>, Marko Folić<sup>4,5</sup>**

<sup>1</sup>Academy of Professional Studies Šabac,  
Department of Medical and Business-Technological Studies, Šabac, Serbia

<sup>2</sup>Pharmacy Vranje, Vranje, Serbia

<sup>3</sup> Pharmacy Pharmanova, Derventa, Bosnia and Herzegovina

<sup>4</sup>University of Kragujevac – Faculty of Medical Sciences, Kragujevac, Serbia

<sup>5</sup>University Clinical Center Kragujevac, Department of Clinical Pharmacology,  
Kragujevac, Serbia

\*roland.antonic@gmail.com

Medicines, alcohol and psychoactive substances have the potential to negatively affect driving ability, which increases the risk of traffic accidents, especially among professional drivers (1, 2). The aim of this research was to examine the use of driving impairing medicines, alcohol and psychoactive substances in the population of professional drivers. The research was conducted as a multicenter cross-sectional study in the Republic of Serbia and Bosnia and Herzegovina. The research population was consisted of 221 professional drivers, both genders, aged from 20 to 65, with a minimum of 2 years driving experience. Average age was 42.82 years. Driving impairing medicines were used by 9.95% of participants, while four of them used three or more of these medicines, most common anxiolytics (45.00%) and antidepressants (17.50%). Alcohol was consumed by 47.96% of respondents (32.08% often), while 53.39% of them were driving under the influence of alcohol. Psychoactive substances were used by 6.33% of respondents, of which twelve abused benzodiazepines, while one marijuana. Significantly lower levels of knowledge and attitudes of respondents about the impact of various psychoactive substances on the driving ability were confirmed among consumers of driving impairing medicines, alcohol and others ( $p<0.001$ ). These results can be explained by inadequate penal policy and insufficient awareness of the respondents about the negative impact of psychoactive substances on the driving ability. The high prevalence of the use of driving impairing medicines, alcohol and psychoactive substances in the examined population was confirmed by this research, which can consequently pose a danger to traffic safety.

### References

1. Downey LA, Hayley AC. Prescription medication use and crash risk: taking responsibility for a new global challenge. Lancet Public Health. 2021;6(6):349-50.
2. Dini G, Bragazzi NL, Montecucco A, Rahmani A, Durando P. Psychoactive drug consumption among truck-drivers: a systematic review of the literature with meta-analysis and meta-regression. J Prev Med Hyg. 2019;60(2):124-39.

## **UPOTREBA LEKOVA SA NEGATIVNIM UTICAJEM NA VOŽNJU, ALKOHOLA I OSTALIH PSIHOAKTIVNIH SUPSTANCI U POPULACIJI PROFESIONALNIH VOZAČA**

**Roland Antonić<sup>1\*</sup>, Milica Pešić Ivanović<sup>2</sup>, Danijela Jevtić<sup>3</sup>, Slobodanka Bogdanović Vasić<sup>1</sup>, Kosana Popović<sup>1</sup>, Nikola Beljić<sup>1</sup>, Danijela Damnjanović<sup>1</sup>, Slobodan Janković<sup>4,5</sup>, Marko Folić<sup>4,5</sup>**

<sup>1</sup>Akademija strukovnih studija Šabac,  
Odsek za medicinske i poslovno-tehnološke studije, Šabac, Srbija

<sup>2</sup>Apoteka Vranje, Vranje, Srbija

<sup>3</sup>Apoteka Pharmanova, Derventa, Bosna i Hercegovina

<sup>4</sup>Univerzitet u Kragujevcu – Fakultet medicinskih nauka, Kragujevac, Srbija

<sup>5</sup>Univerzitetski klinički centar Kragujevac, Služba za kliničku farmakologiju,  
Kragujevac, Srbija

\*roland.antonic@gmail.com

Lekovi, alkohol i ostale psihomotorne sposobnosti, imaju potencijal da negativno utiču na psihomotorne sposobnosti, odnosno sposobnost vožnje, povećavajući rizik od saobraćajnih nezgoda (1). Upotreba ovih supstanci je naročito zabrinjavajuća među profesionalnim vozačima (2). Cilj rada je bio ispitivanje upotrebe lekova sa negativnim uticajem na vožnju, alkohola i ostalih psihomotornih supstanci u populaciji profesionalnih vozača. Istraživanje je sprovedeno kao multicentrična studija preseka, u Republici Srbiji i Bosni i Hercegovini. Istraživačku populaciju je činio 221 profesionalni vozač, oba pola, starosti od 20 do 65 godina, sa minimum 2 godine vozačkog iskustva. Prosečna starost ispitanika bila je 42,82 godine. Lekove sa negativnim uticajem na vožnju koristilo je 9,95% učesnika istraživanja, od kojih je četvoro koristilo tri ili više ovakvih lekova. Od lekova sa negativnim uticajem na vožnju, najčešća je bila primena anksiolitika (45,00%) i antidepresiva (17,50%). Alkohol je konzumiralo 47,96% ispitanika, od toga 32,08% često, dok je pod dejstvom alkohola vozilo 53,39% učesnika istraživanja. Psihomotorne supstance koristilo je 6,33% ispitanika, od toga jedan marijuanu, dok je kod dvanaest zabeležena nemedicinska upotreba (zloupotreba) benzodiazepina. Statistički značajno niži nivoi znanja i stavova ispitanika o uticaju različitih psihomotornih supstanci na sposobnost vožnje su potvrđeni među konzumentima lekova sa negativnim uticajem na vožnju, alkohola i ostalih psihomotornih supstanci ( $r<0,001$ ). Ovi rezultati se mogu objasniti neadekvatnom kaznenom politikom i nedovoljnom upoznatošću ispitanika sa negativnim uticajem psihomotornih supstanci na sposobnost vožnje. Ovim istraživanjem je potvrđena visoka prevalenca upotrebe lekova sa negativnim uticajem na vožnju, alkohola i psihomotornih supstanci u ispitivanoj populaciji, što posledično može predstavljati opasnost po bezbednost saobraćaja.

### **Literatura**

1. Downey LA, Hayley AC. Prescription medication use and crash risk: taking responsibility for a new global challenge. *Lancet Public Health*. 2021;6(6):349-50.
2. Dini G, Bragazzi NL, Montecucco A, Rahmani A, Durando P. Psychoactive drug consumption among truck-drivers: a systematic review of the literature with meta-analysis and meta-regression. *J Prev Med Hyg*. 2019;60(2):124-39.